Cite
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
MLA
Carlos E. Vigil, et al. “Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML).” Blood, vol. 132, Nov. 2018, p. 30. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........9e6aee5911f6bd62719206c87ac6019e&authtype=sso&custid=ns315887.
APA
Carlos E. Vigil, Joshua F. Zeidner, Stephen P. Anthony, Pau Montesinos, Moshe Yair Levy, Andrew Dalovisio, Jeffrey Schriber, David J. Bearss, Daniel J. Lee, Tara L. Lin, Juan Miguel Bergua Burgues, Eunice S. Wang, Mark G. Frattini, & B. Douglas Smith. (2018). Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 132, 30.
Chicago
Carlos E. Vigil, Joshua F. Zeidner, Stephen P. Anthony, Pau Montesinos, Moshe Yair Levy, Andrew Dalovisio, Jeffrey Schriber, et al. 2018. “Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML).” Blood 132 (November): 30. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........9e6aee5911f6bd62719206c87ac6019e&authtype=sso&custid=ns315887.